Filing Details
- Accession Number:
- 0000904454-19-000517
- Form Type:
- 13G Filing
- Publication Date:
- 2019-06-21 16:52:07
- Filed By:
- Ginkgo Bioworks, Inc.
- Company:
- Synlogic Inc. (NASDAQ:SYBX)
- Filing Date:
- 2019-06-21
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Ginkgo Bioworks, Inc | 8,888,888 | 0 | 8,888,888 | 0 | 19.99% |
Filing
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___)* |
| Synlogic, Inc. |
| (Name of Issuer) |
| Common Stock, $0.001 par value |
| (Title of Class of Securities) |
| 87166L100 |
| (CUSIP Number) |
| June 11, 2019 |
| Date of Event Which Requires Filing of this Statement |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of
Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 87166L100
| 1 | Name of Reporting Person: Ginkgo Bioworks, Inc. I.R.S. Identification No. of above Person (entities only) (voluntary) | ||||
| 2 | Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ | ||||
| 3 | SEC USE ONLY | ||||
| 4 | Citizenship or Place of Organization Delaware | ||||
| NUMBER OF | 5 | SOLE VOTING POWER 8,888,888* | |||
| SHARES BENEFICIALLY OWNED BY | 6 | SHARED VOTING POWER 0 | |||
| EACH REPORTING PERSON | 7 | SOLE DISPOSITIVE POWER 8,888,888* | |||
| WITH | 8 | SHARED DISPOSITIVE POWER 0 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED 8,888,888* | ||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 19.99% ** | ||||
| 12 | TYPE OF REPORTING PERSON CO | ||||
* Includes 6,340,771 shares of Common Stock and 2,548,117 shares of Common Stock issuable upon exercise of Warrants.
** Based on 31,729,414 shares of Common Stock outstanding as of June 11, 2019, comprised of (i) 25,388,643 shares of Common
Stock outstanding as of May 2, 2019, as reported in the Issuer’s Report on Form 10-Q for the period ended March 31, 2019 filed with the Securities and Exchange Commission on May 9, 2019 and (ii) 6,340,771 shares of Common Stock issued by the Issuer
in a private placement on June 11, 2019 pursuant to which the Reporting Person acquired the securities reported herein, such 8,888,888 shares of Common Stock represent approximately 25.9% of the Common Stock outstanding, however the terms of the
Warrants include a beneficial ownership limitation pursuant to which the Warrants are exercisable only to the extent that such exercise does not result in the Reporting Person’s beneficial ownership exceeding 19.99% of the Common Stock outstanding
at any time.
CUSIP No. 87166L100
SCHEDULE 13G
| Item 1(a) | Name of Issuer: Synlogic, Inc. |
| Item 1(b) | Address of Issuer’s Principal Executive Offices: 301 Binney Street, Suite 402, Cambridge, MA 02142 |
| Item 2(a) | Name of Person Filing: Ginkgo Bioworks, Inc. (the “Reporting Person”) |
| Item 2(b) | Address of Principal Business Office, or if None, Residence: 27 Drydock Avenue, 8th Floor, Boston, MA 02210 |
| Item 2(c) | Citizenship or Place of Organization: Delaware |
| Item 2(d) | Title of Class of Securities: Common Stock, $0.001 par value (the “Common Stock”) |
| Item 2(e) | CUSIP Number: 87166L100 |
| Item 3 | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is:
Not Applicable |
| Item 4 | Ownership: The information set forth in the cover page to this Schedule 13G is incorporated herein by reference thereto. |
| Item 5 | Ownership of Five Percent or Less of the Class: Not Applicable |
| Item 6 | Ownership of More than Five Percent on Behalf of Another Person: Not Applicable |
| Item 7 | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent
Holding Company: Not Applicable |
| Item 8 | Identification and Classification of Members of the Group: Not Applicable |
| Item 9 | Notice of Dissolution of Group: Not Applicable |
| Item 10 | Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having
such purpose or effect. |
CUSIP No. 87166L100
SIGNATURE
After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set
forth in this statement is true, complete and correct.
Date: June 19, 2019
| GINKGO BIOWORKS, INC. | |||
| By: | /s/ Reshma Shetty | ||
| Name: | Reshma Shetty | ||
| Title: | Attorney-in-Fact | ||
4